18,479 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Bryce Point Capital LLC

Bryce Point Capital LLC bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the fourth quarter, Holdings Channel.com reports. The firm bought 18,479 shares of the company’s stock, valued at approximately $808,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Captrust Financial Advisors boosted its position in shares of Revolution Medicines by 4.1% during the third quarter. Captrust Financial Advisors now owns 8,459 shares of the company’s stock worth $384,000 after buying an additional 337 shares during the period. Verition Fund Management LLC bought a new stake in Revolution Medicines during the 3rd quarter valued at $645,000. Edgestream Partners L.P. acquired a new position in Revolution Medicines during the 3rd quarter worth $1,745,000. Erste Asset Management GmbH bought a new position in shares of Revolution Medicines in the third quarter worth $1,210,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Revolution Medicines by 32.3% during the third quarter. Janus Henderson Group PLC now owns 6,137,244 shares of the company’s stock valued at $278,280,000 after purchasing an additional 1,497,026 shares during the period. Institutional investors own 94.34% of the company’s stock.

Insider Transactions at Revolution Medicines

In related news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now owns 115,006 shares of the company’s stock, valued at approximately $4,489,834.24. This trade represents a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark A. Goldsmith sold 11,738 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $458,251.52. Following the sale, the insider now directly owns 441,564 shares of the company’s stock, valued at $17,238,658.56. This trade represents a 2.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 over the last quarter. Company insiders own 8.00% of the company’s stock.

Analyst Upgrades and Downgrades

RVMD has been the subject of several research analyst reports. Needham & Company LLC reduced their price objective on shares of Revolution Medicines from $60.00 to $59.00 and set a “buy” rating for the company in a report on Thursday, February 27th. HC Wainwright upped their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Wedbush reiterated an “outperform” rating and set a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. UBS Group upped their target price on Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lowered their price target on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday. Twelve analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $65.23.

Revolution Medicines Stock Up 2.9 %

Shares of NASDAQ RVMD opened at $34.60 on Thursday. Revolution Medicines, Inc. has a 12 month low of $29.55 and a 12 month high of $62.40. The company has a market cap of $6.43 billion, a price-to-earnings ratio of -9.64 and a beta of 1.46. The business has a fifty day simple moving average of $39.97 and a 200-day simple moving average of $45.42.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). As a group, sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.